Today: 5 March 2026
Subscribe
Browse Category

Earnings Reports 29 October 2025 - 30 October 2025

eBay Stock Soars on Earnings Beat, Stumbles on Weak Holiday Outlook

eBay Stock Soars on Earnings Beat, Stumbles on Weak Holiday Outlook

eBay shares surged to a 52-week high above $101 after Q3 2025 earnings beat estimates, with revenue up 9% to $2.82 billion and EPS at $1.36. The stock dropped 7–9% in after-hours trading on Oct. 29 after executives issued a weaker-than-expected holiday profit forecast, citing macro pressures and new tariffs. Year-to-date, eBay is up about 60%. Analyst targets remain split, with the average in the low $90s.
30 October 2025
··
Ford (F) Stock Surges on Earnings – Rally Faces EV & Recall Challenges

Ford (F) Stock Surges on Earnings – Rally Faces EV & Recall Challenges

Ford shares jumped 10% after Q3 earnings beat forecasts, closing near a one-year high at around $13. Revenue hit $50.5 billion, up 9% year-over-year, but the company cut 2025 profit guidance by up to $2 billion due to a supplier fire. Ford’s EV unit continues to post losses, and the automaker faces record recalls and higher labor costs. The dividend resumed at $0.15 per share, with most analysts rating the stock a “Hold.”
30 October 2025
···
Sprouts Farmers Market Stock Plunges 25% on Mixed Q3 Earnings – Analysts Scramble

Sprouts Farmers Market Stock Plunges 25% on Mixed Q3 Earnings – Analysts Scramble

Sprouts Farmers Market shares plunged 25% to near $82 on Oct. 30 after Q3 revenue missed estimates and management cut its Q4 sales outlook. Net sales rose 13% to $2.20 billion and EPS beat forecasts, but Q4 comparable-store growth was guided to just 0–2%. UBS and BMO lowered price targets, citing slowing momentum. The stock’s technical indicators showed severe oversold conditions.
30 October 2025
··
Baxter Stock Plummets 15% After Mixed Q3 Earnings – What Investors Should Know

Baxter Stock Plummets 15% After Mixed Q3 Earnings – What Investors Should Know

Baxter shares fell about 16% to $19 on Oct. 30 after cutting its 2025 outlook and missing Q3 sales forecasts. Q3 revenue rose 5% to $2.84 billion, but sales missed estimates; adjusted EPS of $0.69 beat expectations. The company halted Novum IQ infusion pump shipments after two patient deaths and reported hurricane-related supply disruptions. Andrew Hider became CEO in July.
30 October 2025
·
Guardant Health (GH) Stock Rockets on Earnings Beat and New Cancer-Screening Wins

Guardant Health (GH) Stock Rockets on Earnings Beat and New Cancer-Screening Wins

Guardant Health shares soared nearly 30% to around $94 on Oct. 30, 2025, after Q3 revenue jumped 39% to $265.2 million, beating estimates. The company raised its 2025 revenue outlook to $965–970 million. New partnerships are expanding access to its Shield colorectal cancer test nationwide. Guardant360 received additional FDA approvals and a formal review submission.
30 October 2025
··
Medical Properties Trust Defies Skeptics: Q3 Beat and Buyback Ignite 6%‑Yield REIT Rally

Medical Properties Trust Defies Skeptics: Q3 Beat and Buyback Ignite 6%‑Yield REIT Rally

Shares of Medical Properties Trust closed near $5.00 on Oct. 30, 2025, up 3–4% after Q3 earnings beat expectations, valuing the company at $3 billion. Management authorized a $150 million share buyback and reported improved rent collections. The REIT pays a quarterly dividend of $0.08 per share after recent cuts. Short interest remains high at 37% of float, while institutional ownership stands at 58%.
30 October 2025
··
Bristol Myers Squibb (NYSE:BMY) Surges on Q3 Earnings Beat and Raised Outlook – What’s Next for BMY Stock?

Bristol Myers Squibb (NYSE:BMY) Surges on Q3 Earnings Beat and Raised Outlook – What’s Next for BMY Stock?

Bristol Myers Squibb reported Q3 adjusted EPS of $1.63 on $12.2 billion revenue, beating estimates, and raised its 2025 outlook. Shares rebounded 3–4% after hitting a 52-week low, with dividend yield now near 5.5%. New drugs like Opdivo and Eliquis outperformed, offsetting a sharp Revlimid decline. The company acquired Orbital Therapeutics and launched schizophrenia drug Cobenfy, posting $62 million in early sales.
30 October 2025
··
Altria Stock Slips After Mixed Q3 Earnings – Big Buyback and 8% Dividend Tempt Investors

Altria Stock Slips After Mixed Q3 Earnings – Big Buyback and 8% Dividend Tempt Investors

Altria reported Q3 net revenue down 3% to $6.07 billion and adjusted EPS of $1.45, matching estimates. Shares fell nearly 4% pre-market, trading about 10% below recent highs. The company doubled its buyback program to $2 billion and raised its 2025 earnings outlook floor. Cigarette and oral tobacco sales declined, while NJOY e-cigarette sales remain halted due to a patent dispute.
30 October 2025
···
Comcast Shocker: Cord-Cutting Slows, Wireless Soars in Q3 Earnings

Comcast Shocker: Cord-Cutting Slows, Wireless Soars in Q3 Earnings

Comcast Q3 net income fell 8.2% to $3.33 billion, but adjusted EPS of $1.12 and revenue of $31.2 billion beat forecasts. Broadband and pay-TV subscriber losses slowed, while Xfinity Mobile added a record 414,000 lines. Peacock’s EBITDA loss narrowed to $217 million, and theme park revenue rose nearly 19%. Free cash flow jumped 45% to $4.9 billion; shares rose about 2% pre-market.
30 October 2025
··
Mastercard Stock Rockets on Q3 Earnings Beat and $2B Crypto Play – What Investors Should Know

Mastercard Stock Rockets on Q3 Earnings Beat and $2B Crypto Play – What Investors Should Know

Mastercard reported Q3 2025 revenue of $8.60 billion, up 17% year-over-year, with net profit rising 20% to $3.96 billion. Shares traded near $570 in October, up about 8% year-to-date and close to their 52-week high. The company announced support for major US dollar stablecoins and is in late-stage talks to acquire crypto firm ZeroHash for up to $2 billion. About 80% of analysts rate the stock a buy.
30 October 2025
···
Biogen Stock Slides on Q3 Beat as Guidance Cut Shocks Investors

Biogen Stock Slides on Q3 Beat as Guidance Cut Shocks Investors

Biogen shares fell about 2.6% after hours Oct. 30 following Q3 results that beat estimates, with revenue at $2.53 billion and adjusted EPS of $4.81. The company cut 2025 non-GAAP EPS guidance to $14.50–$15.00, citing a $1.25 per-share R&D charge. Leqembi sales reached $121 million, up 80% year-over-year. Biogen licensed Vanqua Bio’s inflammation drug for up to $1.06 billion.
30 October 2025
··
Cigna (CI) Rallies on Q3 Beat & Rebate-Free Drug Plan – Is a 25% Upside in Sight?

Cigna (CI) Rallies on Q3 Beat & Rebate-Free Drug Plan – Is a 25% Upside in Sight?

Cigna shares closed at $299.12 on Oct 29, down 3% for the week, before rising to $303 in Oct 30 premarket trading. The company reported Q3 revenue of $69.7 billion and net income of $1.87 billion, beating forecasts and reaffirming its full-year outlook. Cigna launched a new pharmacy benefit model and Evernorth invested $3.5 billion in Shields Health. Analyst consensus remains bullish with a $370–$377 price target.
30 October 2025
···
Merck (MRK) Stock Could Skyrocket: Key Drug Approvals & Analyst Targets Unveiled

Merck (MRK) Stock Dips on Earnings Beat — Will Pipeline Boost Spur a Rally?

Merck shares fell about 2% after hours Oct. 30 despite Q3 revenue of $17.28 billion and $2.58 adjusted EPS, both above estimates. Keytruda sales rose 10% to $8.1 billion. The company narrowed its 2025 sales outlook and raised profit guidance. Recent milestones include FDA approval of subcutaneous Keytruda and the $10 billion acquisition of Verona Pharma.
30 October 2025
···
Inside Samsung: How the Tech Giant is Dominating Every Industry It Touches

Samsung Stock Soars on AI Chip Boom – Q3 Earnings Crush Estimates

Samsung Electronics shares jumped 3.6% to ₩104,100 on October 30, hitting a 52-week high after Q3 revenue reached ₩86.1 trillion and operating profit rose 32% to ₩12.2 trillion, fueled by record AI chip sales. The company plans major expansion of high-bandwidth memory production for AI servers. Samsung also launched its first Galaxy XR headset and announced a DRAM supply deal with OpenAI.
30 October 2025
····
Bubble or Boom? Magnificent Seven Stocks Face Critical Earnings Showdown

Alphabet (GOOG) Hits Record High on Q3 Earnings Beat, AI Boom Fueling Rally

Alphabet shares jumped 6% to a record high near $270 on Oct. 30 after third-quarter earnings and revenue beat forecasts. Google’s ad revenue rose 12.6% to $74.2 billion, and cloud sales surged 34% to $15.16 billion. The company raised 2025 capital spending to as much as $93 billion for AI and cloud expansion. Wall Street remains bullish, with most analysts rating the stock a “Buy.”
30 October 2025
····
Chipotle Stock Tumbles on Third Forecast Cut — Can the Burrito Chain Bounce Back?

Chipotle Stock Craters After Tepid Q3 Earnings – What’s Next for CMG?

Chipotle shares plunged 18% pre-market Oct. 30 after management cut its 2025 same-store sales forecast to a low-single-digit decline, citing persistent macroeconomic pressures. Q3 revenue rose 7.5% to $3.0 billion, but same-store sales grew just 0.3% as customer traffic fell for the third straight quarter. Chipotle opened 84 new restaurants and repurchased $686.5 million in stock. The stock is down 34% year-to-date.
30 October 2025
···
Fiserv Earnings Miss Expectations, Shares Slide – What’s Next for the Fintech Giant?

Shock Selloff: Fiserv (FI) Stock Plunges 40% After ‘Shockingly Bad’ Q3, Major Shakeup Unveiled

Fiserv shares plunged about 42% to a 52-week low near $66 on Oct. 29, 2025, after missing Q3 estimates and slashing 2025 guidance. Adjusted EPS came in at $2.04 on $4.92 billion revenue, both well below forecasts. CEO Mike Lyons announced a turnaround plan and major leadership changes. The company will move its listing from NYSE to Nasdaq on Nov. 11.
30 October 2025
··
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly Stock on Fire: GLP-1 Bonanza, Big Earnings & AI Pivot Drive Rally

Eli Lilly reported Q3 2025 revenue of $17.60 billion, up 54% year-over-year, and raised full-year EPS guidance to $23.00–23.70. Shares closed at $813.53 on Oct. 29, down 2% over the week after hitting highs above $850 earlier in the month. The FDA approved Inluriyo for metastatic breast cancer, and the EU cleared Kisunla for early Alzheimer’s. Wall Street’s average 12-month price target stands near $939.
30 October 2025
···
1 … 215 216 217 218 219 … 226
Go toTop